AP NEWS
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Globe Newswire
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

BeiGene to Present at Upcoming Investor Conferences

March 4, 2019

CAMBRIDGE, Mass., and BEIJING, China, March 04, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the company will present at two upcoming investor conferences:

-- The Cowen and Company 39th Annual Health Care Conference in Boston on Monday, March 11th at 4:10 p.m. ET; and -- The 2019 Barclays Global Healthcare Conference in Miami on Wednesday, March 13th at 3:20 p.m. ET.

Live webcasts can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/ and archived replays will be available for 90 days following the event.

About BeiGeneBeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,200 employees in China, the United States, Australia and Switzerland, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i

Investor Contact Craig West +1 857-302-5189 ir@beigene.com

Media ContactLiza Heapes+1 857-302-5663 media@beigene.com

i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.